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Abstract
Background & objectives: Trypanosoma lewisi is a common, flagellated parasite of the rat. Our
previous study showed that rabbits injected with serum collected from rats infected with Trypanoso-
ma lewisi and treated with cyclophosphamide (CyI) produced high levels of antibodies against a new
protein in the CyI rat serum.
Results: In the present study, this protein was characterised as α2 macroglobulin (α2M) and the
kinetics of its production and its influence on the malignancy of the disease were determined. In rats
infected with T. lewisi, α2M was first demonstrated and peaked on the second day post-infection
(972 μg/ml) and then reduced gradually, reaching a level of 32 μg/ml on the eighth day post-infec-
tion. However, in the CyI rats the level of α2M was gradually increased as the disease progressed,
reaching a level of 890 μg/ml on the eighth day post-infection. Injection of both crude and purified
α2M into rats infected with T. lewisi led to increased parasitaemia.
Interpretation & conclusion: The present study suggests that increased levels of α2M in the CyI rats
contribute to the malignancy of the disease.
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Introduction
Trypanosoma lewisi is an obligatory, flagellated par-
asite of the rat with a world wide distribution. Sim-
ilar to African trypanosomes, T. lewisi has two bio-
logical forms: epimastigote, in the insect’s intestine
and trypomastigote, in the rat blood1. The parasite is
naturally transmitted to the rats by fleas by either the
inoculation or the contamination pathways1. Unlike
the African trypanosomes, T. lewisi has no antigenic
variation and therefore, the disease in the rat is self-
terminated, leading to a total elimination of the par-
asites and protection of the rats against re-infection2.
The cured rats are resistant to re-infection with T.
lewisi. Despite the fact that the rats naturally over-
come the disease, a lethal infection can be mediated
by the administration of an immunosuppressive agent
like cyclophosphamide (Cy) or by splenectomy. In
both cases, a severe malignant disease with a very
high (50–60%) parasitaemia develops that kills the
rats within 10–15 days post-infection3.
Previous studies performed in our laboratory showed
that injection of rabbits with sera collected from
heavily infected rats that were treated with Cy (CyI),
led to the production of antibodies against most of theBUDOVSKY et al : T. LEWISI  INFECTED RATS 129
serum components, and against a new protein that was
not detected in normal rat serum (N)4. The aim of the
present study was, therefore, to isolate this protein
from CyI rat serum, to characterise it, to determine the
nature of its production, and to examine its influence
on the malignancy of T. lewisi infection.
Material & Methods
Animals: Male rabbits supplied by Yokneam Compa-
ny (Yokneam, Israel), weighing 2.5–3 kg were immu-
nised against rat’s sera and α2M and their sera were
used in immunological tests. Male and female Lewis
rats (Specific pathogen free), supplied by Harlan
Company (Rehovot, Israel) weighing 150–450 g were
used for T. lewisi growth and as a source of sera from
treated infected rats.
Parasites: T. lewisi parasites were obtained from the
American Type Culture Collection (strain number
30022, Manassas, USA) and kept in rats and as a sta-
bilate at –70oC. Rats were inoculated intra-peritoneal-
ly (ip) with 1 ml saline containing 2 ×106 trypano-
somes. At various times post-infection, blood samples
were collected from either the tail or directly from the
heart of ether-anesthetised animals. The parasitaemia
was determined by counting the live parasites by
haemocytometer or by calculating the number of try-
panosomes vs 1 × 104 erythrocytes, in Giemsa’s
stained preparation.
Statistical analysis: Results in each experiment are
summarised as the mean parasitaemia values and the
standards of deviation (SD).
Parasites’  homogenate: The blood was first collect-
ed from infected rats, using heparin as anticoagulant.
The blood was centrifuged at 2000 rpm for 10 min
(Beckman centrifuge) at room temperature, and the
parasites that were concentrated in the upper part were
collected, washed ×3 with saline and centrifuged
again at 3000 rpm for 10 min at room temperature.
The pellet was then resuspended in saline and brought
to a concentration of 2 × 107 parasites/ml. A homo-
genate was prepared by five cycles of freezing and
thawing, followed by a sonication at medium power
five (Sonifier cell disruptor B-30, Branson Sonic
Power, Danbury, CT, USA) using three pulses, each
lasting 30 sec. The homogenate obtained was centri-
fuged at 14000 rpm for 10 min at 4oC. The superna-
tant was collected and the pellet was washed three
times with saline and finally resuspended in 50% of
the original volume. Both the supernatant and the
pellet were kept at –20oC until used.
Effect of various treatments on T. lewisi development
in rats: Rats, weighing 150–220 g were inoculated ip
with 1–2×106  trypanosomes. The infected rats were
either further inoculated ip with a single dose of cy-
clophosphamide (Cy, 10 mg/100 g, Cytophosphan,
Taro, Taro Pharm Indust Ltd, Haifa, Israel) (CyI) or
were splenectomised (SpI)4. Normal uninfected rats
inoculated with Cy only (Cy) were used as control.
In addition, normal and infected rats, either treated or
untreated with Cy, were inoculated ip with a single
dose of 0.25 ml of turpentine oil (Tp) (Sigma)5, or
were injected daily ip, with 1.25–2.5 mg/100 g mer-
captopurine (6-Mercaptopurine, Sigma)6.
Rabbits immunisation: Rabbits (2.5–3 kg) were in-
jected eight times, at a 10 days intervals, with 1 ml
of either CyI or Tp rat serum mixed (vol/vol) with
Complete Freund’s Adjuvant (CFA, Sigma). Approx-
imately 10 days after each injection, a blood sample
was collected, the serum was separated and tested for
anti-α2M antibody activity by immunodiffusion (ID)
and immunoelectrophoresis (IEP), prior and after its
absorbance to normal rat serum. Rabbits were also
immunised against anti-α2M/α2M immune com-
plexes and α2M fraction extracted from both, agar gel
and SDS polyacrylamide gel.
Immunological tests: ID, IEP and IMB were per-
formed as previously described5. ID and IEP were
performed in 0.9% agar gel and the results were re-
corded in fresh preparations and after staining with130 J  VECT  BORNE  DIS  44, JUNE 2007
amido black. IMB was performed, using both native
(without detergents) and SDS-PAGE gels as previ-
ously described5. The concentration of α2M in rats’
sera was determined using a radial immunodiffusion
made in 0.7% agarose solution in PBS buffer6. The
test was performed on a 8 × 10 cm glass slide covered
with 8 ml of (pre-heated to 55oC) rabbit anti-α2M
serum (RαSgel) diluted 1:10 in agarose solution. The
diameters of the precipitation circle lines obtained
were measured and the level of α2M in each sample
was calculated based on a standard curve (R2, mm),
obtained from samples with known α2M concentra-
tions (N and Tp rat sera)7.
α2M purification: α2M was purified from rat sera by
column chromatography and by extraction from agar
gel. Sera samples from rats were first fractionated on
a Sephadex G-100 column (40–120 μm beads, Phar-
macia fine chemicals), using borate saline buffer
(BSB) as elution buffer. Before fractionation, the sera
were dialysed overnight against 300–400 vol of BSB,
at 4oC. The fraction containing α2M eluted from
Sephadex G-100 column was further fractionated on
a DEAE52-cellulose (DE32) (Whatman, 40–120 μm
beads) column, using Tris-HCl buffer containing:
0.03M–0.2M NaCl as eluant gradient. Before frac-
tionation, sera samples were dialysed overnight at
4oC against 250–300 vol of Tris-HCl buffer. In both
cases, fractions of 3.5 ml were collected by a fraction
collector (LKB, Bromma, Ultrarac 7000), and the
optical density (OD) at 280 nm wavelength of each
fraction was determined by a spectrophotometer
(Genesys 5, Spectonic). The eluted fractions from
each peak were concentrated to a 0.5–1 ml volume
and examined for the presence of α2M by ID, IEP and
IMB. For the α2M extraction from gel, sera samples
(0.25–0.5 ml) were first separated by EP in 1.1%
noble agar gel for 1.5–2 h, at a constant 80 V voltage.
After separation, one gel was fixed for an hour using
a fixative solution (40 vol %Ethanol; 2 vol %acetic
acid) and stained with amido black in order to visu-
alise the α2M band. Another gel was cut into 0.5 cm
width slices and the slice containing α2M was re-
moved and transferred to a tube containing 2 ml sa-
line. After overnight incubation at 4oC, the tubes were
centrifused at 14000 rpm for 10 min at 4oC and the
soluble fraction was collected, concentrated to 1 ml
volume and examined for the presence of α2M as
previously described.
Effect of α2M on T. lewisi development: The effect of
α2M on T. lewisi development in vivo in experimen-
tally infected rats was determined using both purified
(gel extraction, antigen-antibody complexes) and
non-purified (CyI and Tp rat sera) α2M. SI rats were
inoculated ip three times, on the day of infection and
on the second and the fourth day post-infection with
0.5 ml of either CyI or Tp rat sera or purified α2M
originated from 0.5 ml Tp rat serum.
Results
T. lewisi development in rats: The development of T.
lewisi in SI, SpI and CyI rats is summarised in Fig.
1. In the SI rats the parasites were first observed on
the second day post-infection. The parasitaemia
peaked (8.4%) on the fifth day and then gradually
decreased, reaching 2–3% ± SD on the eighth day.
During the first week of infection small, big and di-
viding and non-dividing forms were observed that
were transformed into elongated non-dividing para-
sites during the late stage of the disease. In the CyI and
the SpI rats the parasitaemia was gradually increased,
reaching maximal values of 40–50% ± SD on the
eighth day of infection (Fig. 1). Until the fifth day, the
parasitaemia in the SpI rats was lower than that in the
CyI group, after which it was almost similar in both
the groups. During all the experiments, trypanosomes
of various size as well as diving and non-dividing
forms were present (Fig. 1).
Rabbits immunisation: As expected, rabbits immu-
nised against either CyI or Tp rat sera produced an-
tibodies against α2M and against most of the rat sera
components. Absorption of the immune rabbit sera to
normal rat sera removed most of the contaminatingBUDOVSKY et al : T. LEWISI  INFECTED RATS 131
normal serum components (Fig. 2). Immunisation of
rabbits against α2M/anti-α2M immune complexes
showed the production of antibodies against α2M and
against several contaminating serum components,
probably due to non-specific absorption. Also, rabbits
immunised against α2M extracted from agar gel pro-
duced antibodies against α2M  and against other
contaminating components of the rat serum. The most
purified anti-α2M antibodies were obtained in rabbits
immunised against α2M extracted from SDS gel,
showing antibodies against α2M and also against an
additional component, probably α1M.
α2M purification and characterisation: α2M that
was demonstrated in the first peak eluted from the
Sephadex G-100 column was contaminated with five
additional proteins. Further, fractionation of this frac-
tion on a DE32 column removed four of the contam-
inating proteins. α2M was eluted from the DE32
column at 0.09M NaCl. Extraction of α2M from CyI
rat serum by agar gel electrophoresis, followed by a
fractionation on the Sephadex G-100 column elimi-
nated most of the rat serum proteins, but two that
contaminated the α2M preparation.
α2M was characterised in rats sera by affinity chro-
matography, ID, IEP, EP and IMB. The results ob-
tained showed total homology between α2M from
CyI and Tp-treated rats (Fig. 2). Also the location of
α2M demonstrated by EP, IEP and IMB confirmed
the α2M characteristic of this protein. Native α2M is
a slightly negatively charged molecule of a 720 kDa
(native PAGE+IMB), that is separated into four iden-
tical subunits of 180 kDa by SDS-PAGE (Fig. 3).
α2M was neither detected in normal and Cy-treated
rats sera nor in homogenate of parasites. The level of
α2M produced in rats was in the following order: Tp-
treated rat (2nd day post-treatment) >CyI (eighth day
post-treatment)> SpI (eighth day post-treatment).
Effect of α2M on T. lewisi development: The immu-
nosuppressive effect of α2M is well demonstrated in
Fig.1: Trypanosoma lewisi development in saline treated (SI), cyclophosphamide treated (CyI) and spenectomised
(SpI) rats. The rats, weighing 150–200 g, were ip injected with 1 × 106  parasites and the parasitaemia was
determined as the ratio of the T. lewisi parasites to 1 × 104 erythrocytes. Inside the graph from top to bot-
tom-Giemsa stained blood slides taken from the SI, CyI and SpI rats on the eighth day post-treatment
(X 1000 magnification)
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Fig. 2: Anti-α2M antibody activity produced in rabbits immunised against sera from
cyclophosphamide-treated  infected rat (R1) and turpentine-treated normal
rat (R2). The rabbit sera (R1, R2) were adsorbed to normal rat serum before
testing (N–Normal rat serum; CyI–Cyclophosphamide treated infected rat
serum; SpI– Spelenctomised infected rat serum; TLH–T .lewisi homogenate;
and Tp–Turpentine treated uninfected rat serum)
Fig. 3: Immunoblot analysis of rat sera in 7.5% SDS-PAGE (middle) and 5% native
PAGE (left), using serum from rabbit immunised against cyclophosphamide-
treated infected rat serum, as an antibody. The rabbit serum was absorbed with
normal rat serum before applying to the test (N–Normal rat serum; CyI–Cyclo-
phosphamide treated infected rat serum; Tp–Turpentine treated rat serum; and
M–Molecular weight marker)
rats infected with T. lewisi. Inoculation of infected rats
with sera from either CyI or Tp-treated (α2M induc-
er) rat  increased the peak parasitaemia (sixth day
post-treatment) by 4 and 7%, compared to that of SI
rats, respectively (Fig. 4). The injection of  purified
α2M of agar gel origin also led to the increased peak
parasitaemia compared to the SI control (12% ± SD
compared to 7%  ± SD). The most significant effect
of α2M was observed in rats inoculated with anti-
α2M/α2M immune complexes showing as high as
two times higher parasitaemia compared to that of the
control group (15% ± SD compared to 7% ± SD) (Fig.
4). At the end of the experiment (eighth day post-treat-
ment) the parasitaemia in all treated groups reducedBUDOVSKY et al : T. LEWISI  INFECTED RATS 133
Fig. 4: Effect of α2M on Trypanosoma lewisi development in rats. Rats, weighing 150–
170 g, were first infected ip with 1× 106 trypanosomes and then were either left un-
treated (SI) or were treated with cyclophosphamide (CyI), anti-α2M/α2M immune
complexes (SICom), turpentine (TpI), cyclophosphamide + turpentine (CyTpI), mer-
captopurine (MI), or mercaptopurine + cyclophosphamide (MCyI)
to a level similar to that of the control rats. In addi-
tion, the injection of Tp (inducer of α2M production)
into infected rats led to an increased parasitaemia that
reached its peak on the seventh day post-treatment
(19% ± SD), while inhibition of α2M production by
mercaptopurine reduced the parasitaemia to 2–3% ±
SD in the SI rats and to 23% ± SD in the CyI rats (Fig.
4).  A combined treatment of rats with Tp and Cy led
to the highest parasitaemia values on the eighth day
post-treatment that were even higher than those of the
CyI rats (55%  ± SD compared to 45% ± SD).
α2M production in rats: Determining the kinetics of
α2M production by RID showed no change in α2M
level (11–32 μg/ml) in the sera of both normal unin-
fected and Cy-treated rats during the experiment (Fig.
5). In the normal infected (SI), splenectomised infect-
ed (SpI) and Tp-treated infected (TpI) rats a maximal
level of α2M (972 μg/ml, 1869 μg/ml, 3023 μg/ml,
respectively) was demonstrated on the second day
post-infection. These levels were then reduced grad-
ually reaching a level of 300–600 μg/ml, on the eighth
day of infection (Fig. 5). A different pattern of α2M
production was observed in the CyI-treated rats. In
this group the α2M level gradually increased during
experiment reaching a maximal level of 890 μg/ml on
the eighth day post-infection (Fig. 5).  Combined
treatment of infected rats with Cy and Tp induced an
additive α2M activity, reaching a value of 1781 μg/
ml on the eighth day of infection. As expected, a
mercaptopurine treatment of infected rats either un-
treated or treated with Cy significantly inhibited α2M
synthesis, showing a maximal α2M level of 182 μg/
ml (Cy untreated) and 231 μg/ml (Cy treated), on the
second and the fourth day post-infection, respectively
(Fig. 5).
Discussion
The present study confirms again our previous study4
indicating the immunosuppressive action of both
splenectomy and Cy treatment on T. lewisi develop-
ment in rats. Both treatments were associated with the
production of a new component, that was shown to134 J  VECT  BORNE  DIS  44, JUNE 2007
Fig. 5: Kinetics of α2M production in rats (150–200 g) infected with 1 × 106 Trypanosoma lewisi. The rats
were either left untreated (SI), or were splenectomised (SpI), treated with cyclophosphamide (CyI),
turpentine (TpI), cyclophosphamide + turpentine (CyTpI), mercaptopurine (MI), or mercaptopurine+
cyclophosphamide (MCyI)
be, by various procedures, an α2M globulin. Frac-
tionation of α2M, its travelling in gels and its cross
reactivity with α2M from Tp-treated rats confirmed
the α2M nature of this protein. Also, the most puri-
fied α2M preparation was obtained by its extraction
from SDS gel, as was shown by antibodies produced
in rabbits. However, this fraction was still contami-
nated with an additional protein, probably alpha 1
macroglobulin (α1M), which has similar physico-
chemical properties to α2M8,9. α2M was further
shown to be of host origin since it was not detected
in neither soluble nor particulate fractions of T. lewi-
si homogenate. α2M was neither demonstrated in
normal nor Cy treated rat sera, indicating that α2M
is either produced only in response to inflammation
(Tp injection) or to infection with various pathogens.
The immunosuppressive effect mediated by α2M,
leading to a malignant T. lewisi infection was further
confirmed in this study. α2M accelerated the infec-
tion with T. lewisi in both splenectomised and Cy-
treated rats, while inhibition of its production by
mercaptopurine led to the development of a moder-
ate disease. It is of interest to mention that while in
the normal-infected (SI), in Tp-treated infected (TpI)
and in the splenectomised-infected (SpI) rats, the
maximal level of α2M was observed on the second
day post-infection, in the Cy-treated infected rats
(CyI) α2M was gradually accumulated during infec-
tion. These results clearly indicate the correlation
between the α2M levels and the inflammatory re-
sponse mediated by the parasites. Furthermore, the
removal of α2M from circulation was severely im-
paired in the CyI rats. Cy is an alkylating agent that
destroys almost every dividing cell, including those
of the reticuloendothelial system10. The depletion of
these cells from the circulation caused by Cy treat-
ment together with the inflammation induced by the
parasites, led to the accumulation of α2M in the CyI
rats11,12. A combined treatment of infected rats withBUDOVSKY et al : T. LEWISI  INFECTED RATS 135
Cy+Tp caused a higher accumulation of α2M due to
the Tp effect on α2M production and the depletion of
macrophages caused by Cy.
In humans, α2M is a constitutive component of the
serum (8–10% protein content) while in rats, it is an
acute phase protein induced by inflammation13, and
its synthesis is induced by IL-6, hepatocyte growth
factor (HGF), IL-1, TGF-β and steroid dexametha-
sone14. α2M is composed of four identical subunits
(180 kDa) and acts as a proteinase inhibitor14. The
binding of proteinases to α2M leads to a conforma-
tional change and activation of the α2M (activated
α2M- Fα2M)15. Fα2M also binds peptides and
cytokines13. The Fα2M-substrate complexes are
cleared from circulation through binding to the α2M
receptor (α2MR) expressed by hepatocytes, fibro-
blasts and macrophages15,16. α2M is a part of innate
immune system and acts against different pathogens
including  parasites—Leishmania and T. cruzi, by
virulence restriction via inhibition of their proteinas-
es17,18. It has many physiological functions besides
being inhibitor and scavenger of proteinases. α2M
binds numerous cytokines and growth factors and
also activates cellular signaling pathways13. It can act
as an immunostimulator or an immunosuppressor de-
pending on its surroundings. Most of the cytokines
that bind to the Fα2M (covalent binding) are usually
removed from the circulation while the cytokines that
bind native α2M (non-covalent binding), like TGF-
β are very stable and can disengage freely from the
complex acting on their cellular targets19.
The results described in this study showed that the
α2M accumulated in the CyI rats further increased the
immunosuppressive effect mediated by Cy. These
results are in contrast to those observed with Amer-
ican trypanosomiasis and leishmaniasis, in which a
decrease in parasites development was found to be
caused by α2M, due to inhibition of parasite proteases
mediated by α2M17,18. It is, therefore, possible that
the immunosuppressive action of α2M in the CyI rats
may be the result of modulation of the αM-oxidative
status during inflammation20. The low affinity bind-
ing of oxidative α2M to the immunosuppressive cy-
tokines (IL-4, TGF-β, IL-10) and its high affinity
binding to the pro-inflammatory ones (IL-6, TNF-α,
IL-2) may allow the activity of the first group only,
leading to severe immunosuppression and the devel-
opment of a malignant disease21.
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